bluebird bio Inc
$
106.71
-2.98 (-2.72%)
| Volume: | 960,483 | Avg Vol (1m): | 573,776 |
| Market Cap $: | 5.90 Bil | Enterprise Value $: | 4.84 Bil |
| P/E (TTM): | 0.00 | P/B: | 3.59 |
| Earnings Power Value | -97.53 |
| Net Current Asset Value | 16.69 |
| Tangible Book | 29.35 |
| Projected FCF | -21 |
| Median P/S Value | 159.7 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 6/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 6.46 |
Cash-To-Debt range over the past 10 years
Min: 4.3, Med: 9.94, Max: 10000
Current: 6.46
| |
| Equity-to-Asset | 0.81 |
Equity-to-Asset range over the past 10 years
Min: -0.8, Med: 0.81, Max: 0.92
Current: 0.81
| |
| Debt-to-Equity | 0.12 |
Debt-to-Equity range over the past 10 years
Min: 0.05, Med: 0.11, Max: 0.18
Current: 0.12
| |
| Debt-to-EBITDA | -0.29 |
Debt-to-EBITDA range over the past 10 years
Min: -0.49, Med: -0.43, Max: -0.28
Current: -0.29
| |
| Piotroski F-Score | 3 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 8.39 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -0.67 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC -118.29%
WACC 17.24%
| ||
Profitability & Growth : 2/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -1199.09 |
Operating Margin range over the past 10 years
Min: -6975.29, Med: -1111.41, Max: -123.62
Current: -1199.09
| |
| Net Margin % | -1158.04 |
Net Margin range over the past 10 years
Min: -6961.76, Med: -1101.32, Max: -125.47
Current: -1158.04
| |
| ROE % | -37.41 |
ROE range over the past 10 years
Min: -52.8, Med: -28.79, Max: -15.15
Current: -37.41
| |
| ROA % | -31.12 |
ROA range over the past 10 years
Min: -50.45, Med: -23.55, Max: -12.47
Current: -31.12
| |
| ROC (Joel Greenblatt) % | -257.29 |
ROC (Joel Greenblatt) range over the past 10 years
Min: -2352.78, Med: -373.3, Max: -186.61
Current: -257.29
| |
| 3-Year Total Revenue Growth Rate | 57.10 |
3-Year Revenue Growth Rate range over the past 10 years
Min: -53.2, Med: 37.2, Max: 200.2
Current: 37.2
| |
| 3-Year Total EBITDA Growth Rate | -51.50 |
3-Year EBITDA Growth Rate range over the past 10 years
Min: -64.6, Med: -51.3, Max: -32.3
Current: -32.3
| |
| 3-Year EPS w/o NRI Growth Rate | -30.50 |
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -159.3, Med: -51.8, Max: -5.2
Current: -30.5
|
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 3.59 |
PB Ratio range over the past 10 years
Min: 1.75, Med: 3.8, Max: 11.75
Current: 3.59
| |
| PS Ratio | 102.24 |
PS Ratio range over the past 10 years
Min: 4.87, Med: 154.15, Max: 493.98
Current: 102.24
| |
| EV-to-EBIT | -7.08 |
EV-to-EBIT range over the past 10 years
Min: -80.5, Med: -12.1, Max: 7.1
Current: -7.08
| |
| EV-to-EBITDA | -7.22 |
EV-to-EBITDA range over the past 10 years
Min: -86.9, Med: -12.4, Max: 7.2
Current: -7.22
| |
| EV-to-Revenue | 84.80 |
EV-to-Revenue range over the past 10 years
Min: -23, Med: 131.9, Max: 412.1
Current: 84.8
| |
| Current Ratio | 8.02 |
Current Ratio range over the past 10 years
Min: 4.55, Med: 9.71, Max: 29.09
Current: 8.02
| |
| Quick Ratio | 8.02 |
Quick Ratio range over the past 10 years
Min: 4.55, Med: 9.71, Max: 29.09
Current: 8.02
| |
| Days Sales Outstanding | 138.63 |
Days Sales Outstanding range over the past 10 years
Min: 86.31, Med: 89.68, Max: 138.63
Current: 138.63
| |
| Days Payable | 5.00 |
Days Payable range over the past 10 years
Min: 5, Med: 5215.54, Max: 7354.03
Current: 5
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -14.30 |
3-Year Share Buyback Rate range over the past 10 years
Min: -16.8, Med: -16.2, Max: -7.8
Current: -14.3
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.64 |
Price-to-Tangible-Book range over the past 10 years
Min: 2.02, Med: 3.9, Max: 7.98
Current: 3.64
| |
| Price-to-Median-PS-Value | 0.67 |
Price-to-Median-PS-Value range over the past 10 years
Min: 0.04, Med: 1.03, Max: 2.66
Current: 0.67
| |
| Earnings Yield (Joel Greenblatt) % | -14.11 |
Earnings Yield (Greenblatt) range over the past 10 years
Min: -22.2, Med: -8, Max: 15.8
Current: -14.11
|
» BLUE's 30-Y Financials
Financials (Next Earnings Date: 2019-11-01)
» Interactive Chart
Peter Lynch Chart
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:BLUE
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325414   SIC : 2836 |
| Compare | SZSE:000661 NAS:JAZZ NAS:TECH NAS:MRNA HKSE:06160 NAS:NBIX NAS:SAGE SZSE:002252 TSE:4587 NAS:SRPT NAS:AMRN NAS:ALNY XAMS:GLPG NAS:EXEL SZSE:002007 NAS:NKTR NAS:ASND BOM:532523 NAS:IONS OCSE:GEN |
| Traded in other countries | BLE.Germany 0HOH.UK |
| Address | 60 Binney Street, Cambridge, MA, USA, 02142 |
| Bluebird Bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. | |
More Statistics
| Revenue (TTM) (Mil) $ | 56.54 |
| EPS (TTM) $ | -11.99 |
| Beta | 2.62 |
| Volatility % | 56.96 |
| 52-Week Range $ | 87.49 - 176.55 |
| Shares Outstanding (Mil) | 55.27 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 3 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | N |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | N |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |